Quick Answer: EU cosmetic stability testing provides evidence that a finished product remains suitable under its proposed storage and use conditions. Brands should plan studies around the actual formulation and market packaging, with documented methods, acceptance criteria and a justified durability conclusion. There is no universal test duration that proves every cosmetic safe for a fixed shelf life. Review the evidence with the manufacturer and qualified safety assessor before release.
Prepared for international beauty brands by MOOYAM. Last reviewed: 5 October 2026. Cover: AI-generated illustration, not an actual MOOYAM laboratory photograph.
What does a stability study establish?
A useful stability study follows a defined product over time under selected conditions, documenting changes and evaluating them against an agreed specification. It supports a product-specific conclusion. It should not be treated as a generic certificate transferable between unrelated formulas, containers or intended uses.
The HPRA cosmetic GMP guide describes stability testing in market packaging to support the assigned durability or period after opening, with results included in the product information file. The commercial implication is straightforward: do not approve a bottle solely because the formula performed acceptably in a different container.
Is there one mandatory EU stability protocol?
ISO/TR 18811:2018 is a technical report offering guidance, not a single prescribed set of test temperatures, parameters or pass/fail criteria. Its public scope emphasizes the diversity of cosmetic products and the manufacturer’s responsibility to specify and justify an appropriate protocol. A supplier saying “tested to ISO” should identify what was actually done and why it fits your product.
Do not translate this flexibility into permission to omit evidence. It means the technical rationale matters. Ask the laboratory and assessor how the planned conditions relate to foreseeable storage, distribution and use. If a protocol was selected for another product family, document why it remains relevant or what needs changing.
How should brands plan the work?
The following is a recommended project workflow, not a government-issued test schedule. It helps purchasing and product-development teams obtain evidence that can be understood and reviewed rather than collecting disconnected certificates.
| Step | Information to settle | Expected record |
|---|---|---|
| Define the product | Formula version, packaging, intended use and proposed durability | Approved study brief |
| Design the study | Conditions, observations, sampling and acceptance criteria | Justified protocol |
| Track observations | Sample identity, dates, results and deviations | Traceable study records |
| Interpret evidence | Relevance to marketed product and remaining uncertainties | Technical conclusion for assessor review |
| Control changes | Formula, supplier, package or usage changes | Documented reassessment decision |
Which characteristics should be discussed?
Depending on the product, a study brief may need to address appearance, odor, consistency, pH, separation, dispensing performance or other relevant specifications. These are examples to discuss with the technical team, not a universal mandatory panel. Identify in advance which measurements matter, how they will be made, and what change would require investigation.
For a pump product, consider the formula and dispensing system together. For a tinted product, agree how any appearance change is recorded. For a multi-component pack, identify each material in contact with the product. Your development brief should make these details explicit so the laboratory does not have to guess the intended commercial presentation.
Stability, compatibility and microbiology: how do they connect?
Stability examines the product’s behavior over time. Packaging compatibility focuses on the product-container combination. Microbiological evaluation addresses a different aspect of safety and quality. These workstreams can inform one another, but the name of one report should not be used to imply that every other question has been answered.
Review our separate guide to EU cosmetic microbiological testing when planning the evidence package. A stability observation sheet is not automatically a challenge-test report. Similarly, a supplier’s material declaration is not a complete stability conclusion for the finished formula.
How long does stability testing take?
Ask for a product-specific schedule. Distinguish time needed to design the protocol, perform observations, review the results and resolve any unexpected findings. A commercial launch date is not evidence that a study is sufficient. Have the technical team explain the basis for any accelerated approach and how its conclusions will be supported.
Avoid simplistic conversion rules such as treating a short period at an elevated temperature as automatic proof of several years of shelf life for every cosmetic. This guide provides no such conversion. The useful question is which evidence supports the proposed claim for this formula and packaging, and what uncertainty remains.
| Stage | Timing driver | Planning action |
|---|---|---|
| Development | Formula and packaging revisions | Identify when the marketed version will be fixed |
| Study execution | Protocol and scheduled observations | Request a written plan, not an unsupported universal deadline |
| Assessment | Complete results and technical interpretation | Allow review time before artwork and launch sign-off |
| After changes or new findings | Impact on the existing conclusion | Obtain a documented decision on additional work |
How are shelf life and period after opening selected?
The HPRA labeling guidance explains that durability and period-after-opening values should be supported by testing evidence in the CPSR, not chosen arbitrarily. The appropriate label information depends on the product and applicable rules. An attractive “12M” symbol copied from another brand does not provide a scientific basis.
Before printing, ask who approved the durability wording and where the supporting conclusion is recorded. Ensure the product described in that conclusion matches the actual stock being manufactured. Coordinate this with the packaging and labeling review, particularly if the bottle, closure, carton instructions or intended use has changed.
What should the safety assessor receive?
The HPRA CPSR guidance describes a two-part report and requires a suitably qualified assessor for Part B. The responsible person must supply complete, correct information and maintain the report through the product lifecycle. Stability records should therefore be intelligible and traceable, not simply a marketing assurance.
- Product and formula identifiers, with the packaging configuration clearly specified.
- Protocol, selected conditions, observations and relevant acceptance criteria.
- Results, departures from the plan and explanations of unexpected changes.
- The technical conclusion and its relationship to the proposed durability information.
- A record of any later change and the decision on whether earlier evidence remains applicable.
This is a practical document-request checklist. The assessor may request additional evidence for the particular product. Agree access and confidentiality arrangements early so proprietary formulation details do not become a last-minute obstacle.
What can the manufacturer provide, and what must the brand decide?
Ask the manufacturer to confirm available formula specifications, sample batches, packaging details, stability records, compatibility information and quality documentation. Where further work is needed, agree its scope, cost and ownership before purchase commitments. Availability depends on the specific project; an article should never be read as proof that a test has already been performed for your product.
The brand should define target markets, sales channels, expected distribution conditions, desired user experience and proposed claims. It should coordinate the release decision with the responsible person and assessor. Keep commercial wishes separate from technical conclusions: a longer shelf life is a proposal to substantiate, not a number to insert because a retailer requested it.
Frequently asked questions
Can I reuse the study for a new bottle?
Have the product-package change assessed. Do not assume a conclusion for one container automatically covers another material, closure or dispensing system.
Is accelerated testing always enough?
There is no universal answer. The technical team must justify the approach and the conclusions for the actual product; a fixed conversion rule is not a substitute.
Does stability testing replace the CPSR?
No. It supplies evidence that contributes to the overall safety assessment and product documentation.
Who should set acceptance criteria?
The competent technical team should define and justify them within the study plan, with the safety assessor’s needs considered. Purchasing staff should not invent criteria after results arrive.
What happens if a sample changes unexpectedly?
Record and investigate the change, assess its relevance and decide what corrective work is required. Do not remove inconvenient observations from the report.
Build testing into your launch plan
MOOYAM provides cosmetic OEM/ODM manufacturing and technical documentation support for international beauty brands. Contact our team with your formulation direction, packaging and launch markets to confirm available records and outstanding work. Our EU compliance timeline guide helps place this work within the wider project.
Regulatory requirements may change. Brands should verify current requirements with the relevant regulatory authority or qualified compliance professional before placing cosmetic products on the market.